{"id":"docetaxel-carboplatin-trastuzumab-patuzumab","safety":{"commonSideEffects":[{"rate":"40-60","effect":"Neutropenia"},{"rate":"30-50","effect":"Anemia"},{"rate":"20-40","effect":"Thrombocytopenia"},{"rate":"20-30","effect":"Neuropathy"},{"rate":"30-50","effect":"Nausea/vomiting"},{"rate":"40-60","effect":"Fatigue"},{"rate":"20-30","effect":"Diarrhea"},{"rate":"5-15","effect":"Cardiac dysfunction"},{"rate":"5-10","effect":"Hypersensitivity reactions"}]},"_chembl":{"chemblId":"CHEMBL1351","moleculeType":"Small molecule","molecularWeight":"371.25"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Docetaxel is a microtubule-stabilizing taxane that prevents cell division; carboplatin is a platinum agent causing DNA damage; trastuzumab (Herceptin) is a HER2-directed monoclonal antibody blocking HER2 signaling; pertuzumab (Perjeta) is a HER2 dimerization inhibitor that prevents HER2 from pairing with other receptors. Together, these agents provide complementary cytotoxic and targeted mechanisms against HER2-positive cancers.","oneSentence":"This combination uses a taxane chemotherapy agent with platinum-based chemotherapy alongside two HER2-targeted monoclonal antibodies to inhibit cancer cell division and HER2-mediated growth signaling.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:09:38.325Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HER2-positive breast cancer (metastatic or locally advanced)"}]},"trialDetails":[{"nctId":"NCT07057427","phase":"PHASE3","title":"Efficacy of Nab-PHP Versus TCbHP in Neoadjuvant Therapy for HER2-positive Early Breast Cancer","status":"RECRUITING","sponsor":"Henan Cancer Hospital","startDate":"2025-06-24","conditions":"Breast Cancer","enrollment":812},{"nctId":"NCT05918328","phase":"PHASE2","title":"Comparing the Efficacy of Nab-PH+Pyrrolitinib and TCbHP in the Neoadjuvant Treatment of HER2 Positive BC","status":"RECRUITING","sponsor":"Henan Cancer Hospital","startDate":"2023-05-03","conditions":"Breast Cancer, HER2-positive Breast Cancer","enrollment":610},{"nctId":"NCT04547907","phase":"PHASE3","title":"A Comparison of Nab-PHP and TCbHP Efficacy in Neoadjuvant Therapy for HER2-positive Early Breast Cancer","status":"RECRUITING","sponsor":"Henan Cancer Hospital","startDate":"2020-09-18","conditions":"Breast Cancer,HER2-positive","enrollment":688}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["TCbHP regimen group"],"phase":"phase_3","status":"active","brandName":"Docetaxel+ carboplatin+ trastuzumab + patuzumab","genericName":"Docetaxel+ carboplatin+ trastuzumab + patuzumab","companyName":"Henan Cancer Hospital","companyId":"henan-cancer-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination uses a taxane chemotherapy agent with platinum-based chemotherapy alongside two HER2-targeted monoclonal antibodies to inhibit cancer cell division and HER2-mediated growth signaling. Used for HER2-positive breast cancer (metastatic or locally advanced).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}